AbCellera Biologics Inc.
ABCLNASDAQHealthcare● Active
$5.42
$-0.20(-3.56%)
Market Cap$1.7B
P/E Ratio—
52W High$6.79
52W Low$2.33
AbCellera Biologics Inc.（ABCL）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ABCL · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $75.13M | $28.83M | $38.02M | $485.42M | $375.20M |
| Cost of Revenue | $28.82M | $0.00M | $0.00M | $66.44M | $45.52M |
| Gross Profit | $46.31M | $28.83M | $38.02M | $418.99M | $329.69M |
| Gross Margin %(computed) | 61.64% | 100.00% | 100.00% | 86.31% | 87.87% |
| Operating Expenses | |||||
| R&D Expenses | $186.83M | $167.26M | $175.66M | $107.88M | $62.06M |
| G&A Expenses | $0.00M | $72.71M | $61.00M | $55.48M | $41.85M |
| Total Operating Expenses | $263.41M | $343.60M | $275.23M | $202.48M | $125.27M |
| Operating Income | ($217.10M) | ($314.77M) | ($237.21M) | $216.51M | $204.41M |
| Operating Margin %(computed) | -288.98% | — | -623.82% | 44.60% | 54.48% |
| Interest Income | $28.33M | $38.47M | $42.25M | $16.08M | $3.33M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $4.04M | $5.22M |
| Income Before Tax | ($177.59M) | ($200.40M) | ($174.03M) | $239.10M | $219.15M |
| Income Tax Expense | ($31.18M) | ($37.54M) | ($27.63M) | $80.58M | $65.69M |
| Net Income | ($146.41M) | ($162.86M) | ($146.40M) | $158.52M | $153.46M |
| Net Margin %(computed) | -194.88% | -564.83% | -385.00% | 32.66% | 40.90% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.49 | $-0.55 | $-0.51 | $0.56 | $0.56 |
| Wtd Avg Shares | 298.71M | 294.33M | 289.17M | 285.06M | 275.76M |
| EBITDA | ($188.28M) | ($204.15M) | ($192.16M) | $260.17M | $239.15M |
| EBITDA Margin %(computed) | -250.61% | -708.04% | -505.35% | 53.60% | 63.74% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · M
深入了解AbCellera Biologics Inc.
关于AbCellera Biologics Inc.（ABCL）损益表
AbCellera Biologics Inc.（ABCL）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，ABCL实现营收$0.08B，毛利润$0.05B（毛利率61.64%），净利润($0.15B)（净利率-194.88%）。
常见问题
ABCL · 4 问AbCellera Biologics Inc.（ABCL）2025财年营收为$0.08B，同比up160.6%。
ABCL revenueABCL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08